| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jantarima Pandaranandaka, Sutthasinee Poonyachoti, Sarinee Kalandakanond-Thongson. Differential effects of exogenous and endogenous estrogen on anxiety as measured by elevated T-maze in relation to the serotonergic system. Behavioural brain research. vol 198. issue 1. 2009-03-30. PMID:19046994. |
in addition, serotonin (5-ht) and its metabolite (5-hiaa), serotonin reuptake transporter (sert) and tryptophan hydroxylase enzyme (tph) were measured at the end of the study and correlated to the task performances. |
2009-03-30 |
2023-08-12 |
rat |
| Michael Y Aksenov, Marina V Aksenova, Janelle M Silvers, Charles F Mactutus, Rosemarie M Booz. Different effects of selective dopamine uptake inhibitors, GBR 12909 and WIN 35428, on HIV-1 Tat toxicity in rat fetal midbrain neurons. Neurotoxicology. vol 29. issue 6. 2009-03-26. PMID:18606182. |
in this study, we found that the selective inhibitor of dopamine transporter (dat) function, 1-[2-[bis(4-fluorophenyl) methoxy]ethyl]-4-(3-phenylpropyl) piperazine (gbr 12909, vanoxerine), but not the selective inhibitors of serotonin and norepinephrine (sert and net) transporters, sertraline and nizoxetine, emulated cocaine-mediated enhancement of tat neurotoxicity in rat fetal midbrain primary cell cultures. |
2009-03-26 |
2023-08-12 |
rat |
| Meredith A Fox, Catherine L Jensen, Helen T French, Alison R Stein, Su-Jan Huang, Teresa J Tolliver, Dennis L Murph. Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice. Psychopharmacology. vol 201. issue 2. 2009-03-24. PMID:18712364. |
neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (sert)-deficient mice. |
2009-03-24 |
2023-08-12 |
mouse |
| Meredith A Fox, Catherine L Jensen, Helen T French, Alison R Stein, Su-Jan Huang, Teresa J Tolliver, Dennis L Murph. Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice. Psychopharmacology. vol 201. issue 2. 2009-03-24. PMID:18712364. |
serotonin transporter (sert) knockout (-/-) mice have an altered phenotype in adulthood, including high baseline anxiety and depressive-like behaviors, associated with increased baseline extracellular serotonin levels throughout life. |
2009-03-24 |
2023-08-12 |
mouse |
| Henricus G Ruhé, Jan Booij, Henk C v Weert, Johannes B Reitsma, Eric J F Franssen, Eric J F Fransen, Martin C Michel, Aart H Schen. Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 34. issue 4. 2009-03-23. PMID:18830236. |
we aimed to reassess the efficacy of paroxetine dose escalation and quantify whether paroxetine dose escalation increases occupancy of the serotonin transporter (sert) more than placebo dose escalation in a randomized controlled trial. |
2009-03-23 |
2023-08-12 |
Not clear |
| Robin Spille. Serotonergic agents and the irritable bowel syndrome: what goes wrong? Current opinion in pharmacology. vol 8. issue 6. 2009-03-19. PMID:18672092. |
several studies have described an excess of 5ht in ibs-d and abnormally low 5ht availability in ibs-c. serotonin transporter (sert) is only weakly expressed in the colon and whether this is further reduced in ibs is unclear with conflicting reports. |
2009-03-19 |
2023-08-12 |
Not clear |
| Robin Spille. Serotonergic agents and the irritable bowel syndrome: what goes wrong? Current opinion in pharmacology. vol 8. issue 6. 2009-03-19. PMID:18672092. |
sert promoter polymorphisms are inconsistently related to ibs subtypes but appear to partly predict response to both 5ht(3) antagonists and 5ht(4) agonists. |
2009-03-19 |
2023-08-12 |
Not clear |
| Lynette C Daw. Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. Pharmacology & therapeutics. vol 121. issue 1. 2009-03-18. PMID:19022290. |
biogenic amine transporters for serotonin, norepinephrine and dopamine (sert, net and dat respectively), are the key players terminating transmission of these amines in the central nervous system by their high-affinity uptake. |
2009-03-18 |
2023-08-12 |
Not clear |
| Anja Winther Fjorback, Heidi Kaastrup Müller, Ove Wibor. Membrane glycoprotein M6B interacts with the human serotonin transporter. Journal of molecular neuroscience : MN. vol 37. issue 3. 2009-03-16. PMID:18581270. |
the serotonin transporter (sert) belongs to a family of sodium- and chloride-dependent neurotransmitter transporters that are responsible for the active re-uptake of the neurotransmitter serotonin from the synapse. |
2009-03-16 |
2023-08-12 |
human |
| Anja Winther Fjorback, Heidi Kaastrup Müller, Ove Wibor. Membrane glycoprotein M6B interacts with the human serotonin transporter. Journal of molecular neuroscience : MN. vol 37. issue 3. 2009-03-16. PMID:18581270. |
the co-expression of sert with m6b results in a significant decrease in sert-mediated serotonin uptake caused by a down-regulation of sert surface expression. |
2009-03-16 |
2023-08-12 |
human |
| Ana M D Carneiro, David C Airey, Brent Thompson, Chong-Bin Zhu, Lu Lu, Elissa J Chesler, Keith M Erikson, Randy D Blakel. Functional coding variation in recombinant inbred mouse lines reveals multiple serotonin transporter-associated phenotypes. Proceedings of the National Academy of Sciences of the United States of America. vol 106. issue 6. 2009-03-10. PMID:19179283. |
further bioinformatic analysis of bxd phenotypes, combined with biochemical evaluation of sert knockout mice, nominates sert-dependent 5-ht signaling as a major determinant of midbrain iron homeostasis that, in turn, dictates iron-regulated da phenotypes. |
2009-03-10 |
2023-08-12 |
mouse |
| J Pratuangdejkul, B Schneider, J-M Launay, O Kellermann, P Manive. Computational approaches for the study of serotonin and its membrane transporter SERT: implications for drug design in neurological sciences. Current medicinal chemistry. vol 15. issue 30. 2009-03-05. PMID:19075665. |
computational approaches for the study of serotonin and its membrane transporter sert: implications for drug design in neurological sciences. |
2009-03-05 |
2023-08-12 |
Not clear |
| J Pratuangdejkul, B Schneider, J-M Launay, O Kellermann, P Manive. Computational approaches for the study of serotonin and its membrane transporter SERT: implications for drug design in neurological sciences. Current medicinal chemistry. vol 15. issue 30. 2009-03-05. PMID:19075665. |
a key step that regulates 5-ht external level is the re-uptake of 5-ht into cells by the 5-ht transporter (sert), which is besides the target of numerous drugs interacting with the serotonergic system. |
2009-03-05 |
2023-08-12 |
Not clear |
| J Pratuangdejkul, B Schneider, J-M Launay, O Kellermann, P Manive. Computational approaches for the study of serotonin and its membrane transporter SERT: implications for drug design in neurological sciences. Current medicinal chemistry. vol 15. issue 30. 2009-03-05. PMID:19075665. |
in this context, studies aiming at characterizing the physicochemical properties of 5-ht as well as the biological active conformation of sert are a prerequisite to the design of new leads. |
2009-03-05 |
2023-08-12 |
Not clear |
| J Pratuangdejkul, B Schneider, J-M Launay, O Kellermann, P Manive. Computational approaches for the study of serotonin and its membrane transporter SERT: implications for drug design in neurological sciences. Current medicinal chemistry. vol 15. issue 30. 2009-03-05. PMID:19075665. |
in this review, we compared several in silico methods dedicated to the modeling of 5-ht and sert with an emphasis on i) quantum chemistry for study of 5-ht conformation and ii) ligand-based (qsar and pharmacophore models) and transporter-based (homology models) approaches for studying sert molecule. |
2009-03-05 |
2023-08-12 |
Not clear |
| Henricus G Ruhé, Wendy Ooteman, Jan Booij, Martin C Michel, Martina Moeton, Frank Baas, Aart H Schen. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenetics and genomics. vol 19. issue 1. 2009-03-03. PMID:18987562. |
in major depressive disorder, selective serotonin reuptake inhibitors target the serotonin transporter (sert). |
2009-03-03 |
2023-08-12 |
Not clear |
| Leonard L Howel. Nonhuman primate neuroimaging and cocaine medication development. Experimental and clinical psychopharmacology. vol 16. issue 6. 2009-03-03. PMID:19086766. |
selective serotonin transporter (sert) inhibitors were also effective in reducing cocaine use and blocked cocaine-induced brain activation and increases in extracellular dopamine. |
2009-03-03 |
2023-08-12 |
Not clear |
| Alain M Gardie. Mutant mouse models and antidepressant drug research: focus on serotonin and brain-derived neurotrophic factor. Behavioural pharmacology. vol 20. issue 1. 2009-03-03. PMID:19179848. |
basal neurochemical and behavioral changes occurring in mice lacking the 5-ht transporter (sert), which is the main target of antidepressant drugs, as well as in those lacking g protein-coupled serotonin receptors (e.g. |
2009-03-03 |
2023-08-12 |
mouse |
| Terence Y C Pang, Xin Du, Michelle S Zajac, Monique L Howard, Anthony J Hanna. Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease. Human molecular genetics. vol 18. issue 4. 2009-02-27. PMID:19008301. |
female hd mice had an additional deficit in cortical expression of serotonin transporter (sert). |
2009-02-27 |
2023-08-12 |
mouse |
| Werner Zitterl, Martin Aigner, Thomas Stompe, Karin Zitterl-Eglseer, Karin Gutierrez-Lobos, Thomas Wenzel, Georg Zettinig, Kurt Hornik, Walter Pirker, Kenneth Tha. Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 33. issue 13. 2009-02-19. PMID:18354388. |
to the authors' knowledge there is as of yet no study demonstrating in vivo alterations in human serotonin transporters (sert) during clomipramine treatment in patients with obsessive-compulsive disorder. |
2009-02-19 |
2023-08-12 |
human |